<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2653">
  <stage>Registered</stage>
  <submitdate>29/01/2010</submitdate>
  <approvaldate>29/01/2010</approvaldate>
  <nctid>NCT01060475</nctid>
  <trial_identification>
    <studytitle>Safety and Tolerability of LIM-0705 in Healthy Male Subjects</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 Given With or Without Tacrolimus in Healthy Male Subjects</scientifictitle>
    <utrn />
    <trialacronym>LIM</trialacronym>
    <secondaryid>LIM-0705-CL-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LIM-0705 and tacrolimus
Treatment: drugs - LIM-0705 and tacrolimus
Treatment: drugs - Placebo LIM-0705 and tacrolimus
Treatment: drugs - Drug LIM-0705 and placebo tacrolimus

Experimental: A - Low dose LIM-0705 and tacrolimus.

Experimental: B - High dose LIM-0705 and tacrolimus.

Experimental: C - Placebo LIM-0705 and tacrolimus.

Experimental: D - High dose LIM-0705 and placebo tacrolimus.


Treatment: drugs: LIM-0705 and tacrolimus
Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.

Treatment: drugs: LIM-0705 and tacrolimus
Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.

Treatment: drugs: Placebo LIM-0705 and tacrolimus
Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.

Treatment: drugs: Drug LIM-0705 and placebo tacrolimus
Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of LIM-0705 with and without co-administered drug (tacrolimus).</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of LIM-0705 with and without combination of co-administered drug (tacrolimus).</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male age 18-50

          -  Patient in good health as deemed by pre-study exam and history

          -  BMI 20-30 kg/sq. meter

          -  Absence of tremors

          -  Must be willing to remain in confinement for 17 days/16 nights

          -  Systolic BP 90-140 mmHg, diastolic BP 50-90 mmHg, resting HR 45-90 bpm

          -  Subject must be non-smoker or willing to abstain from smoking day -4 through day 30.

          -  Subject must abstain from alcohol, grapefruit,and caffeine-containing beverages
             starting Day -2 through Day 30.

          -  Subjects must use double-barrier contraception through course of study + 90 days
             following study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Allergy to red wine or onions

          -  Strict vegetarians

          -  Use of any non-study medication

          -  Use of chemotherapy within 5 years prior to Screening visit

          -  Use of any dietary aids

          -  Difficultly swallowing oral medications

          -  cognitive or psychiatric disorders</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>44</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network CCS-Austin - Heidelberg</hospital>
    <hospital>Nucleus Network CCS-AMREP - Prahran</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3181 - Prahran</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Limerick BioPharma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>LIM-0705 dosed separately and in combination with tacrolimus will be safe and well tolerated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01060475</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Albert Frauman, MD</name>
      <address>Nucleus Network</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>